People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pluton Biosciences, LLC | — | Biotechnology | Series B | $25.3M | $223.8M | 2023 |
Charles Lin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles Lin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clay Mitchell | 1 | 5 |
| Neal Gutterson | 1 | 3 |
| Elizabeth Gallegos | 1 | 3 |
| BARRY GOLDMAN | 1 | 2 |
| Glendon Schuster | 1 | 2 |
| Gerald Steiner | 1 | 2 |
| Michael Gillespie | 1 | 1 |
| Charles Walch | 1 | 1 |
| Steven Slater | 1 | 1 |
| Wesley Selke | 1 | 1 |
| Charlie Walch | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.